High expression of MALAT1 decreased cisplatin sensitivity in lung cancer, and the mechanism is associated with upregulated Multidrug resistance-associated protein 1 (MRP1) and Multi-Drug resistance 1 (MDR1) via STAT3 [50]. The gene discussed is STAT3; the disease is lung carcinoma.